SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 /PRNewswire/ — Titan Prescribed drugs, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) currently introduced that it has commenced a course of action to investigate and evaluate strategic possibilities to improve shareholder benefit. Titan has engaged Maxim Team LLC as its distinctive monetary advisor to assist in this process.
Likely strategic options that may perhaps be explored or evaluated as aspect of this course of action contain an acquisition, merger, reverse merger, other business enterprise mixture, gross sales of property, licensing or other strategic transactions involving the Corporation. There can be no assurance that the exploration of strategic choices will final result in any agreements or transactions, or that, if accomplished, any agreements or transactions will be thriving or on attractive terms. Titan does not be expecting to disclose developments with respect to this procedure unless and till the analysis of strategic options has been done or the board of administrators has concluded that disclosure is appropriate or lawfully necessary.
About Titan Prescribed drugs
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), primarily based in South San Francisco, CA, is a development stage organization producing proprietary therapeutics with its ProNeura® extensive-expression, continual drug supply technological know-how. The ProNeura engineering has the possible to be utilized in producing products for dealing with a number of long-term circumstances, exactly where maintaining regular, all-around-the-clock blood amounts of medication may perhaps gain the affected person and strengthen medical results. Best validation of the ProNeura® delivery method has been exemplified by acceptance of Probuphine in the US (Fda), EU (EMA) and Canada (Well being Canada).
Vital ongoing ProNeura implant courses consist of IND-enabling, non-clinical assessment of TP-2021, a powerful peptide kappa opioid agonist for the very long-phrase cure of severe, continual pruritis, and nalmefene, a mu opioid receptor blocker created to lessen relapse and potential dying from overdose in detoxed people with Opiate Use Ailment. For additional facts about Titan, please go to www.titanpharm.com.
This push launch might include “ahead-looking statements” in just the indicating of Area 27A of the Securities Act of 1933 and Area 21E of the Securities Trade Act of 1934. Such statements include things like, but are not minimal to, any statements relating to our product enhancement programs and any other statements that are not historical information. These kinds of statements require hazards and uncertainties that could negatively impact our small business, operating outcomes, money problem and stock selling price. Aspects that could lead to genuine effects to vary materially from management’s present expectations contain these challenges and uncertainties relating to our capability to increase cash, the regulatory approval method, the development, screening, generation and promoting of our drug candidates, patent and mental property matters and strategic agreements and interactions. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to mirror any alter in our anticipations or any adjustments in situations, ailments or situation on which any this sort of assertion is based mostly, apart from as essential by legislation.
Perspective primary content to obtain multimedia:https://www.prnewswire.com/news-releases/titan-prescribed drugs-to-discover-strategic-alternate options-301448830.html
Supply Titan Prescribed drugs, Inc.